Published in Law and Health Weekly, September 17th, 2005
The patents grant EntreMed intellectual property protection for 2ME2 and derivatives of 2ME2 in oncology and a broad range of nononcology indications, including inflammatory disorders, immune disorders, cardiovascular disorders, and rheumatoid arthritis.
2ME2 is a novel anticancer agent, which is part of a next...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.